Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
Open Access
- 28 December 2020
- journal article
- research article
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 7 (1), e000531
- https://doi.org/10.1136/bmjgast-2020-000531
Abstract
Introduction Cirrhotic patients with portal hypertension can suffer from variceal bleeding or refractory ascites and can benefit from a transjugular intrahepatic portosystemic shunt (TIPS). Post-TIPS hepatic encephalopathy (HE) is a common (20%–54%) and often severe complication. A prophylactic strategy is lacking. Methods and analysis The Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a TIPS (PEARL) trial, is a multicentre randomised, double blind, placebo controlled trial. Patients undergoing covered TIPS placement are prescribed either rifaximin 550 mg two times per day and lactulose 25 mL two times per day (starting dose) or placebo 550 mg two times per day and lactulose 25 mL two times per day from 72 hours before and until 3 months after TIPS placement. Primary endpoint is the development of overt HE (OHE) within 3 months (according to West Haven criteria). Secondary endpoints include 90-day mortality; development of a second episode of OHE; time to development of episode(s) of OHE; development of minimal HE; molecular changes in peripheral and portal blood samples; quality of life and cost-effectiveness. The total sample size is 238 patients and recruitment period is 3 years in six hospitals in the Netherlands and one in Belgium. Ethics and dissemination This study protocol was approved in the Netherlands by the Medical Research Ethics Committee of the Academic Medical Centre, Amsterdam (2018-332), in Belgium by the Ethics Committee Research UZ/KU Leuven (S62577) and competent authorities. This study will be conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. Study results will be submitted for publication in a peer-reviewed journal. Trial registration numbers ClinicalTrials.gov (NCT04073290) and EudraCT database (2018-004323-37).Keywords
Funding Information
- The Netherlands Organisation for Health Research and Development (848017009)
- Norgine B.V. (2018-1782 IIS2018NL89PEARL)
This publication has 30 references indexed in Scilit:
- Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A systematic reviewJournal of Gastroenterology and Hepatology, 2011
- Rifaximin Treatment in Hepatic EncephalopathyThe New England Journal of Medicine, 2010
- Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization ProfilesAntimicrobial Agents and Chemotherapy, 2010
- The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009Hepatology, 2009
- Management of adult patients with ascites due to cirrhosis: An updateHepatology, 2009
- Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient DataGastroenterology, 2007
- Review article: the burden of hepatic encephalopathyAlimentary Pharmacology & Therapeutics, 2007
- Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled studyJournal of Hepatology, 2005
- Effect of Lactitol and Lactulose Administration on the Fecal Flora in Cirrhotic PatientsJournal of Clinical Gastroenterology, 1990
- Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathyDigestive Diseases and Sciences, 1978